2-(4-(2-(4-(1-(2-EthoxyEthyl)-1H-Benzo[d]Imidazol-2-yl)Piperidin-1-yl)Ethyl)Phenyl)-2-mEthylpropanoic Acid 2-(4-(2-(4-(1-(2-乙氧基乙基)-1H-苯并[d]咪唑-2-基)哌啶-1-基)乙基)苯基)-2-甲基丙酸
CAS 202189-78-4 MFCD09837814
化学结构图
SMILES: CCOCCN1C(=NC2C=CC=CC1=2)C1CCN(CCC2C=CC(=CC=2)C(C)(C)C(O)=O)CC1
化学属性
| Mol. Formula | C28H37N3O3 |
|---|---|
| Mol. Weight | 463.62 |
| Melting Point | 200.0 to 204.0 deg-C |
别名和识别编码
| Chemical Name | 2-(4-(2-(4-(1-(2-EthoxyEthyl)-1H-Benzo[d]Imidazol-2-yl)Piperidin-1-yl)Ethyl)Phenyl)-2-mEthylpropanoic Acid |
|---|---|
| CAS Number | 202189-78-4 |
| Synonym | 4-[2-[4-[1-(2-Ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidinyl]ethyl]-?,?-dimethylbenzeneacetic Acid |
| Chemical Name Translation | 2-(4-(2-(4-(1-(2-乙氧基乙基)-1H-苯并[d]咪唑-2-基)哌啶-1-基)乙基)苯基)-2-甲基丙酸 |
| Reaxys-RN | 13851185 |
| MDL Number | MFCD09837814 |
| PubChem Substance ID | 354335500 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Aromatics
- Heterocycles
- Pharmaceuticals
- Intermediates & Fine Chemicals
产品应用
- Bilastine is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
相关文献及参考
- [2]. Jauregizar, N., et al., Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet, 2009. 48(8): p. 543-54.
- Bauchau, V., et al.: Eur. Respir. J., 24, 758 (2004),
- Lehman, J., et al.: Drugs, 66, 2309 (2006),
- Van Cauwenberge, P., et al.: Clin. Exp. Allergy, 30, 891 (2000),
- [1]. Corcostegui, R., et al., Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D, 2005. 6(6): p. 371-84.
- [1]. Corcostegui, R., et al., Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D, 2005. 6(6): p. 371-84.
- [2]. Jauregizar, N., et al., Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet, 2009. 48(8): p. 543-54.
